DALLAS, Aug. 29 - Affiliated Computer Services, Inc. (NYSE: ACS), a premier provider of business process and information technology outsourcing solutions, announced today that it has been awarded an additional information technology (IT) outsourcing contract with GlaxoSmithKline (GSK), the second-largest pharmaceutical company in the world. The contract is valued at $100.5 million over five years.
Under terms of the agreement, ACS will provide remote server management and monitoring services for more than 5,000 UNIX, Wintel, OS390 Mainframe, and Open VMS servers located at GSK data centers in the U.S. and United Kingdom (UK). ACS will also assume responsibility for facility management and data center operations at four key GSK sites: King of Prussia, Pennsylvania; Research Triangle Park, North Carolina; Stevenage, UK; and Brentford, UK. Additionally, ACS will implement 24x7 coverage and establish a new governance model spanning end-to-end transaction management inclusive of capacity planning and quality management system (QMS) support.
ACS became an IT outsourcing partner to GSK in June 2003 when ACS began supporting GSK's legacy business systems. In 2004, ACS signed a subsequent agreement to custom build a new Registration and Medication Ordering System (RAMOS), supporting GSK's RAMOS clinical trials. ACS meets rigorous ongoing hosting requirements for RAMOS, including FDA qualification and validation for infrastructure and operations, as well as 99.999% availability -- one of the highest availability systems in the world.
"Our partnership with GlaxoSmithKline has enabled us to break new ground in delivering global IT outsourcing solutions," said Lynn Blodgett, Group President of ACS Commercial Solutions. "ACS was one of the first providers of IT infrastructure services to manage a remote operation of this magnitude in the pharmaceutical industry. We will not only deliver unparalleled technology and service, but our goal is to measurably reduce the overall trouble ticket volume for both applications and infrastructure components."
Along with its extensive achievements in business process outsourcing, ACS is experiencing tremendous growth in its IT solutions business. A leading IT outsourcing provider across numerous industries, ACS currently operates several large mainframe and midrange data centers, manages numerous networks, and administers desktops around the globe.
GSK is a global, research-based pharmaceutical business with headquarters and registered office in Brentford, UK, and U.S. headquarters in Philadelphia, Pennsylvania. GSK is the number two pharmaceutical company in the world with more than $37 billion in revenues and more than 100,000 employees worldwide. GSK holds a leading position in genomics/genetics and new drug discovery technologies, with an R&D budget of more than $5 billion, or 12% of sales. To learn more, visit GSK on the Web at http://www.gsk.com .
ACS, a FORTUNE 500 company with more than 50,000 people supporting client operations in nearly 100 countries, provides business process and information technology outsourcing solutions to world-class commercial and government clients. The company's Class A common stock trades on the New York Stock Exchange under the symbol "ACS". ACS makes technology work. Visit ACS on the Internet at http://www.acs-inc.com .
The statements in this news release that do not directly relate to historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to numerous risks and uncertainties, many of which are outside the Company's control. As such, no assurance can be given that the actual events and results will not be materially different than the anticipated results described in the forward-looking statements. Factors could cause actual results to differ materially from such forward-looking statements. For a description of these factors, see the Company's prior filings with the Securities and Exchange Commission, including our most recent filing. ACS disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future event, or otherwise.
